Sildenafil Tablet, Film Coated
Product Images NDC 0904-6671

9 FDA label images from Major Pharmaceuticals · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 0904-6671). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 02)

1 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 02)
Chemical structure diagram of sildenafil, showing its molecular composition and arrangement of atoms, with clearly visible rings and functional groups consistent with the active ingredient sildenafil.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A chart showing the fold change and 90% confidence intervals of pharmacokinetic measures (AUC and Cmax) for various interacting drugs relative to sildenafil alone. The chart includes drugs such as atorvastatin, azithromycin, bosentan, cimetidine, erythromycin, Maalox, oral contraceptives, ritonavir, and saquinavir, with corresponding recommendations on dose adjustments or coadministration advisability.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A chart showing fold change and 90% confidence intervals for pharmacokinetic interactions between sildenafil and various drugs, including Acenocoumarol, Atorvastatin, Bosentan, Doxazosin, Ethinyloestradiol, Levonorgestrel, Phenprocoumon, Ritonavir, Saquinavir, and Tolbutamide. Recommendations on dose adjustments or coadministration are provided based on these interactions.*
FDA Label Image

4 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 05)

4 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 05)
A line graph showing change from baseline in meters over 12 weeks of study for different Sildenafil dosages and placebo. The x-axis represents Week 4, Week 8, and Week 12, while the y-axis shows change from baseline values. The graph includes data points with error bars for Placebo, Sildenafil 20 mg TID, Sildenafil 40 mg TID, and Sildenafil 80 mg TID, indicating comparative efficacy over time.*
FDA Label Image

5 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 06)

5 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 06)
A forest plot chart showing placebo-corrected changes in 6-minute walk distance in meters for Sildenafil 20 mg taken three times daily across various subgroups. The subgroups include baseline walk distance, etiology, pulmonary hypertension criteria, gender, age, mean pulmonary arterial pressure, and pulmonary vascular resistance index, each with sample sizes for placebo and Sildenafil groups and plotted confidence intervals.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
A survival curve chart showing the percentage without a clinically worsening event over time in days from randomization, comparing two groups labeled Placebo and Sildenafil. The vertical axis represents the percentage without an event, and the horizontal axis shows days from 0 to 112.*
FDA Label Image

Pi Logo (Logo1)

FDA Label Image

Logo (Logo mg)

FDA Label Image

20mg Carton Label (8b584f5d 8030 4f91 A129 8120f9e1b204 00)

20mg Carton Label (8b584f5d 8030 4f91 A129 8120f9e1b204 00)
This image shows a unit dose packaging label for Sildenafil Tablets, USP, 20 mg strength, film-coated oral tablets by Major Pharmaceuticals. The label includes the NDC number 0904-6671-06 and states a quantity of 50 tablets (5 x 10). It includes dispensing instructions, storage conditions, a caution about child-resistant packaging intended for institutional use only, and manufacturer information including Major Pharmaceuticals, Indianapolis, IN, USA.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.